LUNG conditions are the third biggest killer in the North and the charity Asthma and Lung NI is calling for better diagnosis ...

More must be done to ensure that asthma patients get access to cutting-edge treatments, experts have said, after research ...

New ‘life-changing’ asthma drug gets green light after rise in hospital admissions - A trial cut hospital admissions by 72 ...

The injectable therapy contain antibodies that dampen inflammation in the lungs and is set to revolutionise the way severe ...

An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...

The US FDA has approved depemokimab as an add-on maintenance therapy for individuals aged 12 years or older with severe asthma, according to a press release from manufacturer GlaxoSmithKline.

The parents of a 13-year-old girl who died after an asthma attack led to a cardiac arrest have said they fear "other families will lose children because asthma is too easily dismissed". Emily Albino, ...

Depemokimab has been approved by the MHRA as the first and only biologic with twice-yearly dosing to treat asthma and severe rhinosinusitis.

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but rejected its use for another condition, the drugmaker said on Tuesday.

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment ‍for asthma in patients aged 12 and older, as well as for a chronic inflammatory sinus condition in ...

This indicator covers the percentage of patients with asthma on the register with a risk factor for poor outcomes, who have had an asthma review in the preceding 12 months that includes an assessment ...